Abdelrahman Elsayid

Dr. Abdelrahman Elsayid

School of Public Health, Imperial College London, London, City of London, UK
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2022 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
DHDang The Hung
Dang The Hung
SGSuhaib Ghula
Suhaib Ghula
Jeza Muhamad Abdul AzizJeza Muhamad Abdul Aziz
Jeza Muhamad Abdul Aziz
Abdelrahman ElsayidAbdelrahman Elsayid
Abdelrahman Elsayid
GTGehad Mohamed Tawfik
Gehad Mohamed Tawfik
Nguyen Tien HuyNguyen Tien Huy
Nguyen Tien Huy
This study aimed to evaluate the efficacy and adverse events of favipiravir in patients with COVID-19. Our protocol was registered on PROSPERO (CRD42020206305). Fourteen databases were searched until February 8th, 2021. An update search for new RCTs was done on March 2nd, 2022. Meta-analysis was done for randomized controlled trials (RCTs) and non-RCTs. Overall, 157 studies (24 RCTs, 1 non-RCT, 21 observational studies, 2 case series, and 106 case reports) were included. On hospitalized patients, in comparison to standard of care, favipiravir showed a higher rate of viral clearance at day 5 (RR = 1.60, p = 0.02), defervescence at day 3–4 (RR = 1.99, p <0.01), chest radiological improvement (RR = 1.33, p <0.01), hospital discharge at day 10–11 (RR = 1.19, p <0.01), and shorter clinical improvement time (MD = –1.18, p = 0.05). Regarding adverse events, favipiravir groups had higher rates of hyperuricemia (RR = 9.42, p <0.01), increased alanine aminotransferase (RR = 1.35, p <0.01) but lower rates of nausea (RR = 0.42, p <0.01) and vomiting (R R= 0.19, p=0.02). There were no differences regarding mortality (RR=1.19, p=0.32), and increased aspartate aminotransferase (RR = 1.11, p = 0.25). On nonhospitalized patients, no significant differences were reported. Adding favipiravir to the standard of care provides better outcomes for hospitalized patients with COVID-19. Pregnant, lactating women, and patients with a history of hyperuricemia should avoid using favipiravir.

28 October 2021 in Research in Sports Medicine
Verified
Journal Article
Closed access
LTLinh Tran
Linh Tran
Abdelrahman ElsayidAbdelrahman Elsayid
Abdelrahman Elsayid
Omar Makram ElsayedOmar Makram Elsayed
Omar Makram Elsayed
MEMuhammed Khaled Elfaituri
Muhammed Khaled Elfaituri
SMSara Morsy
Sara Morsy
Nguyen Tien HuyNguyen Tien Huy
Nguyen Tien Huy
Kinesio taping is widely used in musculoskeletal conditions. We performed a systematic review and meta-analysis on the efficacy of kinesio taping in musculoskeletal disorders compared to other interventions. Twelve electronic databases were used for systemic search and data relevant to pain and disability were extracted. The protocol was registered in PROSPERO (CRD42018087606). Meta-analysis was performed to compare the efficacy of kinesio taping to other modalities of musculoskeletal disorders. As a result, 36 studies were included in the quantitative analysis. Kinesio taping was found to provide an improvement of both pain and disability when applied to any region of the body. In the first five days of application, kinesio taping significantly reduced the pain in all body regions (SMD = −0.63, 95%CI: −0.87, −0.39). This was also noted after four-to-six weeks of application (SMD = −0.76, 95%CI: −1.07, −0.45). When kinesio taping was used for disability in low back pain patients, it significantly reduced the disability within five days of application (SMD = −0.70, 95%CI: −1.29, −0.11). Finally, kinesio taping has shown an improvement of the disability in all body regions after four-to-six weeks of application (SMD = −0.59, 95%CI: −0.96, −0.22). Our findings support kinesio taping as an adjuvant to other treatments for musculoskeletal disorders. Abbreviations KT = Kinesio taping; MSK = musculoskeletal; SD = standard deviation; CR = conventional rehabilitation; NDI = Neck Disability Index; NPS = Numerical Pain Scale; CTM = Cervical Thrust Manipulation; PIR = Post-isometric muscle relaxation; NPRS Numerical Pain Rating Scale; OA = osteoarthritis; ROM = Range of motion; VAS = visual analogue scale; VAS-W = visual analogue scale-worst pain; VAS-U = visual analogue scale-usual pain; VAS-R = visual analogue scale-resting pain; VAS-A = visual analogue scale-activity pain; VAS-N = visual analogue scale-night pain; NPDS = Neck Pain Disability Scale; QA = Quality assessment

26 June 2023 in Journal of Professional Nursing
Verified
Journal Article
Closed access
RERanda Elsheikh
Randa Elsheikh
LQLoc Le Quang
Loc Le Quang
NNNgoc Quynh Tram Nguyen
Ngoc Quynh Tram Nguyen
PVPhu Tran Van
Phu Tran Van
DHDang The Hung
Dang The Hung
Nguyen Tien HuyNguyen Tien Huy
Nguyen Tien Huy

30 June 2017 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
MKMohamed Gomaa Kamel
Mohamed Gomaa Kamel
NNNguyen Tran Nam
Nguyen Tran Nam
NHNguyen Huu Bao Han
Nguyen Huu Bao Han
AEAbd-Elaziz El-Shabouny
Abd-Elaziz El-Shabouny
Abdelrahman ElsayidAbdelrahman Elsayid
Abdelrahman Elsayid
Nguyen Tien HuyNguyen Tien Huy
Nguyen Tien Huy
Dengue is one of the most common infectious diseases. The aim of this study was to systematically review acute disseminated encephalomyelitis (ADEM) and to represent a new case. We searched for articles in nine databases for case reports, series or previous reviews reporting ADEM cases in human. We used Fisher’s exact and Mann-Whitney U tests. Classification trees were used to find the predictors of the disease outcomes. We combined findings using fixed- and random-effects models. A 13-year-old girl was admitted to the hospital due to fever. She has a urinary retention. The neurological examinations revealed that she became lethargic and quadriplegic. She had upper limbs weakness and lower limbs complete paraplegia. Her status gradually improved after the treatment. She was nearly intact with the proximal part of her legs had a mild weakness in discharge. The prevalence of ADEM among dengue patients was 0.4% [95% confidence intervals (95% CI) 0.1–2.5%], all neurological disorders among dengue was 2.6% [95% CI 1.8–3.8%], and ADEM among neurological disorders was 6.8% [95% CI 3.4–13%]. The most frequent manifestation of ADEM was altered sensorium/consciousness (58%), seizures and urination problems (35%), vision problems (31%), slurred speech (23%), walk problems (15%) then ataxia (12%). There was a significant difference between cases having complete recovery or bad outcomes in the onset day of neurological manifestations being earlier and in temperature being higher in cases having bad outcomes (p-value < 0.05). This was confirmed by classification trees which included these two variables. The prevalence of ADEM among dengue and other dengue-related neurological disorders is not too rare. The high fever of ADEM cases at admission and earlier onset day of neurological manifestations are associated with the bad outcomes. We presented a 13-year-old girl of ADEM following dengue infection. She was totally alert and had a low grade of fever with no focal neurologic deficits, on admission. We revealed that the prevalence of either ADEM or all neurological disorders among dengue patients was not too rare. Moreover, we found that the most common manifestation of ADEM was altered sensorium/consciousness followed by seizures and urination problems then vision problems. These manifestations should be considered in the diagnosis and management of dengue-infected patients. Also, this requires shedding the light on the total global cases of ADEM from the annual incidence of dengue. The onset of ADEM can be early or late after dengue infection. Hence, clinicians should pay attention that it can be early or late that patients can forget about their fevers. Moreover, the onset day of neurological manifestations and patients’ temperature were significantly associated with the disease outcome.

11 May 2023 in Infectious Medicine
Verified
Journal Article
Open access
RERanda Elsheikh
Randa Elsheikh
Abdelrahman ElsayidAbdelrahman Elsayid
Abdelrahman Elsayid
TVTamilarasy Vasanthakumaran
Tamilarasy Vasanthakumaran
STShubham Tomar
Shubham Tomar
KSKhizer Shamim
Khizer Shamim
Nguyen Tien HuyNguyen Tien Huy
Nguyen Tien Huy
• The world has experienced an unprecedented monkeypox outbreak that started in known endemic countries and spread to nonendemic countries. • The recent outbreak might be an indicator of new viral mutations. • The decrease in smallpox vaccination following its eradication is hypothesized to have contributed to the recent surge in cases. • Mass vaccination using smallpox or monkeypox vaccines may not be efficient. Treating this viral outbreak like COVID-19 should be discouraged.

2 May 2024 in Journal of Burn Care & Research
Verified
Journal Article
Open access
PDF file
RERanda Elsheikh
Randa Elsheikh
Abdelrahman ElsayidAbdelrahman Elsayid
Abdelrahman Elsayid
The global increasing spread of multidrug-resistant organisms (MDROs) is threatening the control of various infections in vulnerable populations and patient groups. One of the most affected groups is patients with burns, who are prone to hyperinfection as they suffer from a hypermetabolic state and weaken immune barriers. Those patients also share the infection risk of patients hospitalized for a long time, including ventilator-associated pneumonia and urinary tract infections. While some preventative and therapeutic management styles are still controversial, we discuss consensuses here. In this review, we aim to present the current knowledge on multidrug resistance with a special focus on patients with burns, discuss various causative organisms and their treatment options, and highlight the importance of antibiotic stewardship and teamwork in responding to an outbreak of MDROs.